BioNTech SE
Market Data Current As Of: September 12, 2026
Related Competitor Intelligence
Compare market positioning with top industry peers
Explore BioNTech
Core profile pages, annual revenue records, and related research hubs for this company.
BioNTech SE
Compare market positioning with top industry peers
Explore BioNTech
Core profile pages, annual revenue records, and related research hubs for this company.
Company History
Founded 2008 in Mainz, Rhineland-Palatinate, Germany
BioNTech SE is a German biotechnology company founded in 2008 in Mainz, Germany, by physicians and immunologists Prof. Ugur Sahin, Prof. Ozlem Tureci, and Dr. Surprisingly, Christoph Huber. BioNTech's single most defensible competitive moat is its integrated mRNA technology platform, developed and refined over more than two decades by co-founders Ugur Sahin and Ozlem Tureci, which combines proprietary uridine mRNA-lipoplex formulation, computational neoantigen prediction algorithms, and in-house GMP manufacturing capabilities that competitors cannot replicate within five years. BioNTech SE traces its origins to the research laboratories of the University of Mainz in the early 2000s, where Ugur Sahin, a Turkish-born physician and immunologist, and Ozlem Tureci, a German physician with Turkish roots, were investigating why cancer immunotherapies failed so frequently in clinical practice. During this period, he and Tureci began adapting multiple technologies for therapeutic use, including antibodies, cell therapies, and mRNA. The founders were supported by early investors including Dr. Thomas and Dr. Andreas Strüngmann, Michael Motschmann, and Helmut Jeggle, who provided the capital to transform academic research into a commercial enterprise. The founding team brought complementary expertise: Sahin as CEO and scientific visionary, Tureci as Chief Medical Officer and clinical strategist, and Huber as a scientific co-founder. On January 25, 2020 — weeks before the World Health Organization declared a pandemic — Sahin launched "Project Lightspeed," directing BioNTech's resources toward developing a mRNA vaccine against SARS-CoV-2. The project used two decades of mRNA platform development that had originally been intended for cancer immunotherapy. Yet the founders consistently emphasized that economic success was secondary to their scientific mission. Throughout the pandemic, they maintained focus on the original vision of cancer immunotherapy, using COVID vaccine profits to fund oncology pipeline expansion.
BioNTech (Biopharmaceutical New Technologies) was founded in 2008 in Mainz, Germany, by a husband-and-wife team of physicians and brilliant scientists: Uğur Şahin and Özlem Türeci, along with Austrian oncologist Christoph Huber. Şahin and Türeci are the children of Turkish immigrants who moved to Germany in the 1960s. They met while working at an university hospital in Homburg, bonding over a shared, obsessive dedication to cancer research (famously spending their wedding day in the laboratory). The foundational vision of BioNTech was radically different from traditional oncology. While pharmaceutical companies were focused on creating blockbuster cancer drugs (chemicals designed to kill tumors broadly, often with horrific side effects), Şahin and Türeci believed that cancer was a personalized disease. Every patient's tumor had an unique genetic mutation. Therefore, the cure had to be personalized. Their goal was to use messenger RNA (mRNA) to instruct a patient's own immune system to recognize and destroy their specific, unique cancer cells. For over a decade, they labored in relative obscurity, constantly struggling to secure funding for their theoretical, unproven mRNA platform. In 2019, they finally took the company public on the NASDAQ, raising capital to fund their cancer trials. Just months later, in January 2020, Şahin read a medical journal article about a mysterious new respiratory virus in Wuhan, China. Recognizing the threat, he immediately initiated 'Project Lightspeed,' pivoting BioNTech's entire mRNA oncology platform toward designing a vaccine for the novel coronavirus over a single weekend. Partnering with Pfizer for global manufacturing and distribution, the founders' decades of obscure, unfunded research culminated in the delivery of a vaccine that saved millions of lives and instantly elevated them into the pantheon of the most consequential scientists in human history.
Prof. Ozlem Tureci, M.D. is the Co-Founder, Chief Medical Officer, and Member of the Management Board of BioNTech SE. A German physician and immunologist with Turkish roots, Tureci trained at Saarland University Medical Center where she met and later married Ugur Sahin in 2002. Her clinical practice in oncology provided the foundational insight for BioNTech's mission: that the genetic heterogeneity of tumors—less than 3% similarity between patients with the same cancer type—was the root cause of treatment failure for standardized therapies. Tureci co-founded BioNTech in 2008 to develop individualized immunotherapies that could address this heterogeneity, initially focusing on mRNA-based cancer vaccines. She has led the clinical development strategy for all BioNTech programs, from the early cancer vaccine trials through the COVID-19 vaccine development and now the oncology pipeline pivot. As Chief Medical Officer, she oversees clinical trial design, regulatory strategy, and medical affairs. Tureci has been instrumental in establishing BioNTech's partnerships with Genentech/Roche, Pfizer, and other global pharmaceutical companies. She has received numerous honors including the German Future Prize (Deutscher Zukunftspreis) in 2021 alongside Sahin for the COVID-19 vaccine development. Tureci's public statements consistently emphasize the goal of translating research into survival for patients worldwide.
Dr. Christoph Huber is a scientific co-founder of BioNTech SE and was previously a co-founder of Ganymed Pharmaceuticals alongside Ugur Sahin and Ozlem Tureci in 2001. At Ganymed, Huber contributed to the development of zolbetuximab, a monoclonal antibody targeting CLDN18.2 for gastric and esophageal cancers, which demonstrated significant overall survival benefit in randomized trials and led to the company's acquisition by Astellas Pharma in 2016 for over $436 million. Huber's expertise in antibody development and translational oncology research informed BioNTech's early technology platform decisions, including the initial focus on multiple therapeutic modalities beyond mRNA. While maintaining a lower public profile than Sahin and Tureci, Huber's scientific contributions were instrumental in establishing the research culture and technical capabilities that enabled BioNTech's later success.
Prof. Ugur Sahin, Prof. Ozlem Tureci, and Dr. Christoph Huber founded BioNTech SE in Mainz, Germany, with initial backing from investors including the Strüngmann brothers, Michael Motschmann, and Helmut Jeggle. The company was established to develop individualized cancer immunotherapies based on mRNA technology, following two decades of academic research at the University of Mainz and Saarland University Medical Center.
Katalin Karikó, the biochemist whose pioneering work on nucleoside-modified mRNA would prove foundational to COVID-19 vaccine development, joined BioNTech as Senior Vice President. Her research on modifying uridine in mRNA to reduce immunogenicity while maintaining translational efficiency was critical to making mRNA therapeutics clinically viable.
BioNTech completed its initial public offering on the Nasdaq Global Select Market under ticker symbol BNTX, raising capital as an emerging growth company and foreign private issuer. The IPO provided funding to advance the oncology pipeline and expand manufacturing capabilities, valuing the company at approximately $3.4 billion at pricing.
On January 25, 2020, Ugur Sahin launched 'Project Lightspeed' to develop a mRNA vaccine against SARS-CoV-2, weeks before the WHO pandemic declaration. In March 2020, BioNTech announced its collaboration with Pfizer Inc. to jointly develop, manufacture, and commercialize the COVID-19 vaccine, with Pfizer providing global infrastructure and BioNTech contributing the mRNA platform.
On December 2, 2020, the Pfizer-BioNTech BNT162b2 vaccine received emergency use authorization from the UK Medicines and Healthcare products Regulatory Agency, becoming the world's first approved mRNA-based medicine and the first COVID-19 vaccine authorized for widespread use. FDA authorization followed on December 11, 2020.
For the fiscal year ended December 31, 2021, BioNTech reported total revenues of $20,684.6 million ($22.0 billion), with net profit of $11,218.8 million and diluted earnings per share of $43.20 ($46.87). The company delivered approximately 2.6 billion doses of Comirnaty to more than 165 countries and regions, including over 1 billion doses to low- and middle-income countries.
Total revenues declined to $18,868.6 million in 2022 as COVID-19 vaccine demand began normalizing, though the company still generated $15,643.8 million in gross profit share from the Pfizer collaboration. BioNTech began explicitly reinvesting pandemic profits into oncology pipeline expansion, increasing R&D expenses and headcount.
Total revenues fell to $4,162.7 million in 2023, a 78% decline from 2022, as COVID-19 vaccine demand collapsed and the virus entered endemic stages. The company maintained profitability with net profit of $1,014.0 million but began accelerating oncology investments, with non-COVID R&D expenses increasing to $1.60 billion.
For fiscal year 2025, BioNTech reported revenue of EUR2.8699B, a net loss of EUR1.1361B, and diluted loss per share of EUR4.70. R&D expenses were EUR2.1049B, and the company maintained EUR17.2356B in cash, cash equivalents, and security investments while guiding 2026 revenues to EUR2.0B-EUR2.3B.
In November 2024, BioNTech signed an agreement to acquire Biotheus for $800 million upfront plus up to $150 million in milestones, securing full global rights to BNT327 (PM8002), a bispecific antibody targeting PD-L1 and VEGF-A. The acquisition, completed in February 2025, added a Chinese R&D hub with over 300 employees and an advanced biologics manufacturing facility.
In August 2025, BioNTech reached agreements with CureVac and GSK to resolve pending patent litigation regarding mRNA technology, agreeing to pay $370 million to GSK plus a 1% royalty on U.S. sales of mRNA COVID-19 and influenza products, with an additional $130 million and 1% rest-of-world royalty contingent on closing the CureVac acquisition.
BioNTech acquired Biotheus to secure full global rights to BNT327 (PM8002), a novel bispecific antibody combining PD-L1 checkpoint inhibition with VEGF-A neutralization. The acquisition also added an in-house antibody generation platform, bispecific ADC capabilities, and a Chinese R&D hub with over 300 employees and an advanced biologics manufacturing facility.
BioNTech acquired Gilead subsidiary Kite Pharma's cell therapy manufacturing facility in Marburg, Germany, to expand mRNA vaccine production capacity for the COVID-19 vaccine program. The facility was rapidly converted to GMP mRNA manufacturing.
BioNTech acquired InstaDeep, a Tunisian-British AI company specializing in deep learning and computational biology, to enhance its neoantigen prediction capabilities and drug discovery platform.
Since its establishment in 2008, BioNTech SE expanded from an early-stage venture into a recognized leader in Biotechnology / Immunotherapy, overcoming key market challenges.
Over its history, BioNTech SE executed decisive strategic pivots toward scalable monetization and digital distribution, securing its current market leadership.
By continually modernizing operations and embracing workflow automation, BioNTech SE maintains resilience through changing technological and economic cycles.